CAPTRUST Financial Advisors
CMPX icon

CAPTRUST Financial Advisors’s Compass Therapeutics CMPX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.4K Buy
32,609
+10,933
+50% +$32.3K ﹤0.01% 3093
2026
Q1 		$115K Buy
21,676
+830
+4% +$4.79K ﹤0.01% 2792
2025
Q4 		$112K Buy
20,846
+322
+2% +$1.49K ﹤0.01% 2598
2025
Q3 		$71.8K Buy
20,524
+199
+1% +$629 ﹤0.01% 2537
2025
Q2 		$52.8K Buy
20,325
+332
+2% +$685 ﹤0.01% 2421
2025
Q1 		$38K Buy
+19,993
New +$53.2K ﹤0.01% 2299

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CAPTRUST Financial Advisors's CMPX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its Compass Therapeutics (CMPX) stake by 50% in Q2 2026, buying an estimated $32.3K and bringing the position to 32,609 shares worth $71.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3093.

CAPTRUST Financial Advisors first reported a position in CMPX in Q1 2025 and has held it in 6 quarters since. The position peaked at $115K in Q1 2026. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • CAPTRUST Financial Advisors held 32,609 shares of Compass Therapeutics worth $71.4K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 10,933 Compass Therapeutics shares in Q2 2026, an estimated $32.3K.
  • Compass Therapeutics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #3093 holding.
  • CAPTRUST Financial Advisors first reported a position in Compass Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • CAPTRUST Financial Advisors's Compass Therapeutics position peaked at $115K in Q1 2026.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.